Insider Selling: Definium Therapeutics (NASDAQ:DFTX) CFO Sells $135,675.39 in Stock

Definium Therapeutics, Inc. (NASDAQ:DFTX) CFO Brandi Roberts sold 3,013 shares of Definium Therapeutics stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total value of $135,675.39. Following the completion of the sale, the chief financial officer owned 209,487 shares of the company’s stock, valued at approximately $9,433,199.61. The trade was a 1.42% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Definium Therapeutics Price Performance

Shares of NASDAQ DFTX opened at $44.95 on Monday. The firm has a market capitalization of $4.48 billion, a P/E ratio of -18.05 and a beta of 2.37. The firm’s 50-day moving average price is $24.59 and its 200-day moving average price is $19.41. The company has a current ratio of 4.69, a quick ratio of 4.69 and a debt-to-equity ratio of 0.15. Definium Therapeutics, Inc. has a 1-year low of $6.40 and a 1-year high of $47.01.

Definium Therapeutics (NASDAQ:DFTX) last announced its quarterly earnings results on Friday, May 8th. The company reported ($0.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.23). Equities research analysts anticipate that Definium Therapeutics, Inc. will post -2.29 earnings per share for the current fiscal year.

Analysts Set New Price Targets

DFTX has been the topic of a number of recent analyst reports. Canaccord Genuity Group set a $60.00 price target on shares of Definium Therapeutics in a research report on Monday, June 22nd. Oppenheimer set a $60.00 price objective on shares of Definium Therapeutics and gave the company an “outperform” rating in a research note on Monday, June 22nd. Robert W. Baird lifted their target price on shares of Definium Therapeutics from $37.00 to $57.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 23rd. Royal Bank Of Canada restated an “outperform” rating on shares of Definium Therapeutics in a research note on Monday, June 22nd. Finally, HC Wainwright upped their target price on Definium Therapeutics from $55.00 to $70.00 and gave the company a “buy” rating in a report on Monday, March 2nd. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $47.08.

Hedge Funds Weigh In On Definium Therapeutics

Several large investors have recently modified their holdings of DFTX. Russell Investments Group Ltd. raised its stake in shares of Definium Therapeutics by 110.4% during the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock valued at $25,000 after purchasing an additional 2,003 shares during the period. BNP Paribas Financial Markets grew its holdings in Definium Therapeutics by 56.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company’s stock valued at $55,000 after buying an additional 3,020 shares in the last quarter. FNY Investment Advisers LLC bought a new stake in shares of Definium Therapeutics during the third quarter valued at about $107,000. Flagship Harbor Advisors LLC purchased a new stake in shares of Definium Therapeutics in the fourth quarter worth about $117,000. Finally, Caxton Associates LLP bought a new position in shares of Definium Therapeutics in the third quarter valued at approximately $126,000. Hedge funds and other institutional investors own 27.91% of the company’s stock.

Trending Headlines about Definium Therapeutics

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: Definium said its Phase III depression program delivered positive results, a key catalyst that can support optimism about eventual approval and commercialization. Definium raises $805 million after positive Phase III depression data
• Positive Sentiment: The company closed an upsized public offering, raising $805 million, which strengthens its balance sheet and reduces near-term financing risk. Definium Therapeutics Announces Closing of $805 Million Upsized Public Offering
• Neutral Sentiment: Several insiders, including the CEO and CFO, sold shares at $45.03. Insider selling can sometimes pressure sentiment, but the transactions were relatively small compared with their remaining holdings. CEO insider filing
• Neutral Sentiment: Market commentary and analyst writeups also pointed to the stock’s sharp move higher after the Phase III news, reinforcing the view that investors are reacting to the clinical-data catalyst. Why Definium Therapeutics, Inc.’s (DFTX) Stock Is Up 15.35%
• Negative Sentiment: Heavy insider selling from multiple executives may temper enthusiasm, as some investors could interpret it as a sign management views the stock as fully valued near recent highs.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.